THE RS1801282 PPARG POLYMORPHISM DEPENDENT METABOLIC EFFECTS OF PIOGLITAZONE IN PATIENTS WITH OBESITY AND CONCOMITANT NAFLD
Abstract
The aim: to investigate the metabolic effects of different treatment options in patients with obesity and concomitant non-alcoholic fatty liver disease (NAFLD) based on the presence of CG and GG genotypes PPARG rs1801282 (Pro12Ala) polymorphism in Ukrainians.
Materials and methods: 123 patients with NAFLD in combination with obesity 1, 2, 3 classes were included in the motivational weight loss program (5 visits, 3 months). The case group was treated with pioglitazone 15 mg / day, while the control group received only a program. Ultrasound steatometry, anthropometric and laboratory tests before and after treatment, genetic testing rs1801282 polymorphism in PPARG gene were performed.
Results: the carriers of CG and GG genotypes PPARG rs1801282 polymorphism had less high stimulated insulin levels compared with groups of different genotypes (p<0.001). It was found pioglitazone effectiveness with significant difference in dynamics of CAP reduction (p<0.001) regardless of polymorphism. Dynamics of BMI decrease was the lowest in control group CC carries – –2.81 (–3.23; –2.39) kg (p<0.001) compared among other groups. Subjects from pioglitazone group with rs1801282 polymorphism carrying of CG and GG genotypes had significant differences in dynamics of fasting С-peptide decrease, serum uric acid reduction – –1.31 (–1.50; –1.13) µg/L and -165.3 (–182.80; –147.80) µmol/L (p<0.001) respectively compared among other groups.
Conclusions: Better reduction of metabolic parameters during pioglitazone treatment of patients with obesity and concomitant NAFLD appears to be associated with carrying of CG and GG genotypes PPARG rs1801282 polymorphism.
Downloads
References
Kovalic, A. J., Banerjee, P., Tran, Q. T., Singal, A. K., Satapathy, S. K. (2018). Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology, 8 (4), 390–402. doi: http://doi.org/10.1016/j.jceh.2018.04.001
Cholankeril, R., Patel, V., Perumpail, B., Yoo, E., Iqbal, U., Sallam, S. et. al. (2018). Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases, 6 (4), 93. doi: http://doi.org/10.3390/diseases6040093
Wang, N., Kong, R., Luo, H., Xu, X., Lu, J. (2017). Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease. PPAR Research, 2017, 1–8. doi: http://doi.org/10.1155/2017/6561701
Lee, Y. K., Park, J. E., Lee, M., Hardwick, J. P. (2018). Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2. Liver Research, 2 (4), 209–215. doi: http://doi.org/10.1016/j.livres.2018.12.001
Wang, Y., Nakajima, T., Gonzalez, F. J., Tanaka, N. (2020). PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice. International Journal of Molecular Sciences, 21 (6), 2061. doi: http://doi.org/10.3390/ijms21062061
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. (2016). Journal of Hepatology, 64 (6), 1388–1402. doi: http://doi.org/10.1016/j.jhep.2015.11.004
Wolf Greenstein, A., Majumdar, N., Yang, P., Subbaiah, P. V., Kineman, R. D., Cordoba-Chacon, J. (2017). Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice. Journal of Endocrinology, 232 (1), 107–121. doi: http://doi.org/10.1530/joe-16-0447
Hall, K. D., Ayuketah, A., Brychta, R., Cai, H., Cassimatis, T., Chen, K. Y. et. al. (2019). Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metabolism, 30 (1), 67–77.e3. doi: http://doi.org/10.1016/j.cmet.2019.05.008
Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S. et. al. (2005). Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia, 48 (4), 634–642. doi: http://doi.org/10.1007/s00125-005-1682-x
Sanchez-Lozada, L. G., Andres-Hernando, A., Garcia-Arroyo, F. E., Cicerchi, C., Li, N., Kuwabara, M. et. al. (2019). Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats. Journal of Biological Chemistry, 294 (11), 4272–4281. doi: http://doi.org/10.1074/jbc.ra118.006158
Barros, R. K., Cotrim, H. P., Daltro, C. H., Oliveira, Y. A. (2017). Hyperferritinemia in patients with nonalcoholic fatty liver disease. Revista Da Associação Médica Brasileira, 63 (3), 284–289. doi: http://doi.org/10.1590/1806-9282.63.03.284
Marunchyn, N., Dynnyk, B., Kobyliak, N., Fedusenko, A., Barannyk, E. (2017). Attenuation coefficient measurement as novel noninvasive ultrasound method for diagnosis ofhepatic steatosis. Endocrinology, 22 (2), 115–120. Available at: https://endokrynologia.com.ua/index.php/journal/article/view/67/59.
Pu, K., Wang, Y., Bai, S., Wei, H., Zhou, Y., Fan, J., Qiao, L. (2019). Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterology, 19 (1). doi: http://doi.org/10.1186/s12876-019-0961-9
World Health Organization (2006). Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF Consultation. Available at: http://www.who.int/diabetes/publications/Definition %20and %20diagnosis %20of %20diabetes_new.pdf Last accessed: 09.04.2016
Bondar, R. J. L., Mead, D. C. (1974). Evaluation of Glucose-6-Phosphate Dehydrogenase from Leuconostoc mesenteroides in the Hexokinase Method for Determining Glucose in Serum. Clinical Chemistry, 20 (5), 586–590. doi: http://doi.org/10.1093/clinchem/20.5.586
Albano, J. D. M., Ekins, R. P., Maritz, G., Turner, R. C. (1972). A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinologica, 70 (3), 487–509. doi: http://doi.org/10.1530/acta.0.0700487
Recommendations for managing type 2 diabetes in primary care (2017). International Diabetes Federation. Available at: www.idf.org/managing-type2-diabetes
Kanda, Y. (2012). Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplantation, 48 (3), 452–458. doi: http://doi.org/10.1038/bmt.2012.244
Leighton, E., Sainsbury, C. A., Jones, G. C. (2017). A Practical Review of C-Peptide Testing in Diabetes. Diabetes Therapy, 8 (3), 475–487. doi: http://doi.org/10.1007/s13300-017-0265-4
Takahashi, K., Nakamura, H., Sato, H., Matsuda, H., Takada, K., Tsuji, T. (2018). Four Plasma Glucose and Insulin Responses to a 75 g OGTT in Healthy Young Japanese Women. Journal of Diabetes Research, 2018, 1–7. doi: http://doi.org/10.1155/2018/5742497
Jones, A. G., Hattersley, A. T. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30 (7), 803–817. doi: http://doi.org/10.1111/dme.12159
Domenici, F. A., Brochado, M. J. F., Martinelli, A. de L. C., Zucoloto, S., da Cunha, S. F. de C., Vannucchi, H. (2013). Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: A study in Brazilian patients. Gene, 529 (2), 326–331. doi: http://doi.org/10.1016/j.gene.2013.06.091
Lombardi, R., Pisano, G., Fargion, S. (2016). Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD. International Journal of Molecular Sciences, 17 (4), 548. doi: http://doi.org/10.3390/ijms17040548
Black, M. H., Wu, J., Takayanagi, M., Wang, N., Taylor, K. D., Haritunians, T. et. al. (2015). Variation inPPARGIs Associated With Longitudinal Change in Insulin Resistance in Mexican Americans at Risk for Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 100 (3), 1187–1195. doi: http://doi.org/10.1210/jc.2014-3246
Copyright (c) 2020 Vadym Shypulin, Nikolai Rudenko, Oleksandr Martynchuk, Aleksandr Koliada, Vitaly Guryanov, Nataliia Melnyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.